在 CAP 和协会共同发布的 MSI/MMR 实践指南于 2022 年发布之前，使用美国病理学家学院 (CAP) MSI/MMR 能力测试计划描述实验室中的错配修复 (MMR) 和微卫星不稳定性 (MSI) 测试实践分子病理学 (AMP) 的。审查了 2020-B MSI/MMR 计划向不同实践环境的 542 个实验室提供的补充问卷数据。调查问卷包含 21 个问题，涉及所进行的检测类型、用于检测的标本/肿瘤类型以及检查点阻断治疗的临床实践。国内实验室检测 MSI/MMR 的频率高于国际实验室 (P = .04) 和学术医院/医疗机构中心的测试比非医院场所/诊所更频繁 (P = .03)。最常用的检测方式是免疫组织化学，其次是聚合酶链反应，然后是新一代测序。大多数实验室 (72.6%; 347/478) 报告对使用免疫检查点抑制剂治疗高 MSI 或 MMR 缺陷结果的患者的认识。结果证明了 CAP 发布之前实验室中 MMR 和 MSI 检测的状态/AMP 最佳实践指南，强调各种实验室类型之间的差异。研究结果表明了共识指南的重要性，并为实施后的比较提供了基线。© 作者 2024。由牛津大学出版社代表美国临床病理学会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

To describe mismatch repair (MMR) and microsatellite instability (MSI) testing practices in laboratories using the College of American Pathologists (CAP) MSI/MMR proficiency testing programs prior to the 2022 publication of the MSI/MMR practice guidelines copublished by CAP and the Association of Molecular Pathology (AMP).Data from supplemental questionnaires provided with the 2020-B MSI/MMR programs to 542 laboratories across different practice settings were reviewed. Questionnaires contained 21 questions regarding the type of testing performed, specimen/tumor types used for testing, and clinical practices for checkpoint blockade therapy.Domestic laboratories test for MSI/MMR more often than international laboratories (P = .04) and academic hospitals/medical centers test more frequently than nonhospital sites/clinics (P = .03). The most commonly used testing modality is immunohistochemistry, followed by polymerase chain reaction, then next-generation sequencing. Most laboratories (72.6%; 347/478) reported awareness of the use of immune checkpoint inhibitor therapy for patients with high MSI or MMR-deficient results.The results demonstrate the state of MMR and MSI testing in laboratories prior to the publication of the CAP/AMP best practice guidelines, highlighting differences between various laboratory types. The findings indicate the importance of consensus guidelines and provide a baseline for comparison after their implementation.© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.